An observational study in Right Ventricular (RV) Dysfunction, sponsored by Abiomed Inc.. Recruiting at 31 sites in United States. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Abiomed Inc. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To capture observational data of the Abiomed Impella RP Flex in a real-world setting.
Abiomed Inc. is the lead sponsor of 34 studies on the registry; 5 are open to participants now.
First submitted after Abiomed Inc. became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
This study includes sites from the US
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Right-sided ventricular assist device
Percutaneous device for right heart support
Objectives
Survival at hospital discharge, with follow-ups at 30 days, 90 days, and 1-year post-discharge of Impella RP patients from real-world surveillance data.
Time frame: 1 year post implant
Started May 2024 (actual). Primary completion is estimated for Apr 2026, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.